204 related articles for article (PubMed ID: 15621837)
1. Eosinophilic leukemic transformation in polycythemia rubra vera (PRV).
Chim CS; Ma SK
Leuk Lymphoma; 2005 Mar; 46(3):447-50. PubMed ID: 15621837
[TBL] [Abstract][Full Text] [Related]
2. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
[TBL] [Abstract][Full Text] [Related]
3. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
[TBL] [Abstract][Full Text] [Related]
4. Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera.
Ellis AK; Lee DH
Am J Hematol; 2002 Nov; 71(3):237-8. PubMed ID: 12410589
[No Abstract] [Full Text] [Related]
5. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
Mavrogianni D; Viniou N; Michali E; Terpos E; Meletis J; Vaiopoulos G; Madzourani M; Pangalis G; Yataganas X; Loukopoulos D
Int J Hematol; 2002 May; 75(4):394-400. PubMed ID: 12041671
[TBL] [Abstract][Full Text] [Related]
6. Hypereosinophilic syndrome associated with polycythemia vera.
Varon D; Wetzler M; Berrebi A
Arch Intern Med; 1986 Jul; 146(7):1440-1. PubMed ID: 3718142
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemia in polycythemia vera.
Landaw SA
Semin Hematol; 1986 Apr; 23(2):156-65. PubMed ID: 3704667
[No Abstract] [Full Text] [Related]
8. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
[TBL] [Abstract][Full Text] [Related]
9. Leukemic transformation in polycythemia vera: analysis of risk factors.
Nand S; Messmore H; Fisher SG; Bird ML; Schulz W; Fisher RI
Am J Hematol; 1990 May; 34(1):32-6. PubMed ID: 2327402
[TBL] [Abstract][Full Text] [Related]
10. [Experience with the 5-hydroxyurea therapy of polycythemia rubra vera].
Nagy G; Szegedi J; Petrányi G
Orv Hetil; 1972 Jun; 113(27):1601-3. PubMed ID: 5040981
[No Abstract] [Full Text] [Related]
11. Paraneoplastic eosinophilic fasciitis: a case report.
Jacob SE; Lodha R; Cohen JJ; Romanelli P; Kirsner RS
Rheumatol Int; 2003 Sep; 23(5):262-4. PubMed ID: 12734672
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
Cacciola E; Cacciola RR; Guglielmo P; Stagno F; Giustolisi R
Haematologica; 1999 Aug; 84(8):755-6. PubMed ID: 10457418
[No Abstract] [Full Text] [Related]
13. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
14. Long-term management of polycythemia vera with hydroxyurea: a progress report.
Kaplan ME; Mack K; Goldberg JD; Donovan PB; Berk PD; Wasserman LR
Semin Hematol; 1986 Jul; 23(3):167-71. PubMed ID: 3749925
[No Abstract] [Full Text] [Related]
15. Pruritus secondary to hydroxyurea therapy in a woman with polycythemia vera.
Vosburgh E
Am J Hematol; 1992 Sep; 41(1):70. PubMed ID: 1503109
[No Abstract] [Full Text] [Related]
16. Chronic myelomonocytic leukemia transformation in polycythemia vera.
Holcombe RF; Treseler PA; Rosenthal DS
Leukemia; 1991 Jul; 5(7):606-10. PubMed ID: 2072746
[TBL] [Abstract][Full Text] [Related]
17. Porokeratosis in patients with polycythemia rubra vera: a new side effect of hydroxyurea?
Kanitakis J; Arbona-Vidal E; Faure M
J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1040-1. PubMed ID: 21812837
[No Abstract] [Full Text] [Related]
18. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
19. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.
West WO
South Med J; 1987 Mar; 80(3):323-7. PubMed ID: 3824016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
